NCT05177731View on ClinicalTrials.gov

"Venetoclax + Decitabine vs. 7+3 Induction Chemotherapy in Young AML"

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

December 31, 2024

Conditions

AML, AdultChemotherapy Effect

Interventions

DRUG

Venetoclax

Orally by mouth

DRUG

Decitabine for Injection

Intravenous infusion

DRUG

Cytarabine

Intravenous infusion

DRUG

Idarubicin

Intravenous infusion

DRUG

Gilteritinib

Orally by mouth

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou

All Listed Sponsors

lead

Chen Suning

OTHER